Eris Lifesciences Ltd. Share Price Today
Techno Funda Ratings
Key Metrics
Current Price
₹1400.6Market Cap
₹ 19,409 Cr.Stock P/E
30.7ROE
18.7 %RSI
26.63Trend
BearishShare Price Chart
Technical Commentary
Buy or Sell Analysis
Company Overview
ERIS Lifesciences Ltd is engaged in the business of manufacture and marketing of pharmaceutical products.[1]
ERIS Lifesciences Ltd share price remains one of the actively tracked stocks on NSE among traders and long term investors.
The latest ERIS Lifesciences Ltd share price NSE movement reflects ongoing investor interest driven by company fundamentals, sector performance and broader market sentiment.
From a technical analysis perspective, the ERIS Lifesciences Ltd share price chart currently indicates a Bearish trend based on moving averages and RSI momentum analysis.
Technical Analysis
| Indicator | Value |
|---|---|
| Current Price | 1400.6 |
| RSI (14) | 26.63 |
| 50 DMA | 1411.26 |
| 200 DMA | 1453.23 |
| Trend | Bearish |
| A/D Rating | B |
| RS Rating | 50 |
| EPS Rating | 50 |
| TI65 | 1.03 |
| TI65 Trend | Neutral |
Pivot Points Analysis
Daily pivot points for Eris Lifesciences Ltd. calculated using previous trading session data. These levels help traders identify intraday support, resistance and breakout zones using Classic Pivot Point methodology.
Classic Pivot Points
| Level | Value |
|---|---|
| R3 | ₹1451.4 |
| R2 | ₹1430.2 |
| R1 | ₹1415.4 |
| PP | ₹1394.2 |
| S1 | ₹1379.4 |
| S2 | ₹1358.2 |
| S3 | ₹1343.4 |
Financial Ratios
| Metric | Value |
|---|---|
| Market Cap | ₹ 19,409 Cr. |
| Current Price | ₹ 1,401 |
| High / Low | ₹ 1,888 / 1,200 |
| Stock P/E | 30.7 |
| Book Value | ₹ 282 |
| Dividend Yield | 0.52 % |
| ROCE | 14.1 % |
| ROE | 18.7 % |
| Face Value | ₹ 1.00 |
Quarterly Results
| Quarter | Sales | Profit | OPM |
|---|---|---|---|
| Mar 2023 | 403 | 61 | 30% |
| Jun 2023 | 467 | 94 | 36% |
| Sep 2023 | 505 | 122 | 36% |
| Dec 2023 | 486 | 101 | 36% |
| Mar 2024 | 551 | 80 | 27% |
| Jun 2024 | 720 | 90 | 35% |
| Sep 2024 | 741 | 96 | 36% |
| Dec 2024 | 727 | 87 | 34% |
| Mar 2025 | 705 | 102 | 36% |
| Jun 2025 | 773 | 125 | 36% |
| Sep 2025 | 792 | 134 | 36% |
| Dec 2025 | 807 | 109 | 35% |
| Mar 2026 | 757 | 279 | 36% |
Shareholding Pattern
| Holder | Holding |
|---|---|
| Promoters | 55.93% |
| FIIs | 8.59% |
| DIIs | 10.82% |
| Public | 24.66% |
| No. of Shareholders | 33,129 |
Pros and Cons
Pros
- Healthy return on equity of 18.7% indicating strong capital allocation efficiency.
Cons
- Primary trend direction remains weak, stuck underneath major defensive supply barriers.
Related NSE Stocks
Sammaan Capital Ltd.
View Share Price Analysis →Navin Fluorine International Ltd.
View Share Price Analysis →Global Health Ltd.
View Share Price Analysis →Exide Industries Ltd.
View Share Price Analysis →Petronet LNG Ltd.
View Share Price Analysis →Fertilisers and Chemicals Travancore Ltd.
View Share Price Analysis →Lemon Tree Hotels Ltd.
View Share Price Analysis →Adani Energy Solutions Ltd.
View Share Price Analysis →JM Financial Ltd.
View Share Price Analysis →Aditya Birla Sun Life AMC Ltd.
View Share Price Analysis →Tech Mahindra Ltd.
View Share Price Analysis →Godawari Power & Ispat Ltd.
View Share Price Analysis →Frequently Asked Questions
What is the current technical trend and RSI for ERIS Lifesciences Ltd share?
Based on the latest closing data, the technical momentum for ERIS Lifesciences Ltd is currently evaluated as Bearish. The stock is exhibiting an RSI (14) of 26.63, indicating it is trading in a technically oversold zone. Key tracking supports are currently located near the daily pivots, with price relative to the 50 DMA (1411.26) defining immediate multi-day trend patterns.
What are the key resistance and support pivot points for ERIS Lifesciences Ltd?
According to Classic Pivot Point methodologies, the core trading floor for ERIS Lifesciences Ltd today centers at a Pivot Point (PP) of ₹1394.2. Upside resistance challenges are calculated at R1: ₹1415.4, R2: ₹1430.2, and R3: ₹1451.4. Conversely, if selling pressure intensifies, immediate floor support targets are positioned at S1: ₹1379.4, S2: ₹1358.2, and S3: ₹1343.4.
How does the fundamental ROE and P/E ratio look for ERIS Lifesciences Ltd?
ERIS Lifesciences Ltd is currently trading with a valuation metrics context of a Stock P/E of 30.7, against a core structural efficiency Return on Equity (ROE) standing at 18.7 %. This fundamental operational efficiency baseline is coupled with an EPS Rating of 50, allowing investors to track how corporate profitability trends align with current price discovery cycles on the National Stock Exchange (NSE).
Should I buy or sell ERIS Lifesciences Ltd shares based on corporate rankings?
Our dynamic trade matrix suggests a status of: Chronic Downtrend / Potential Value Trap (Neutral / Avoid). ERIS Lifesciences Lt... For long-term portfolios, decision-making should match the stock's market performance profile, which currently displays an institutional Accumulation/Distribution (A/D) grade of B, a Relative Strength (RS) ranking of 50, and long-term trend backing from the TI65 indicator (Neutral pattern).